Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Viral vectors for dendritic cell-based immunotherapy.

L Jenne1, G Schuler, A Steinkasserer

  • 1Department Dermatology, University of Erlangen-Nürnberg, Hartmannstrasse 14, D-91052, Erlangen, Germany.

Trends in Immunology
|April 5, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thymic stromal lymphopoietin deficiency attenuates experimental autoimmune encephalomyelitis.

Clinical and experimental immunology·2015
Same author

Soluble CD83 ameliorates experimental colitis in mice.

Mucosal immunology·2014
Same author

Measurement of the ZZ production cross section and limits on anomalous neutral triple gauge couplings in proton-proton collisions at sqrt[s] = 7 TeV with the ATLAS detector.

Physical review letters·2012
Same author

Search for new phenomena in tt events with large missing transverse momentum in proton-proton collisions at sqrt[s] = 7 TeV with the ATLAS detector.

Physical review letters·2012
Same author

Fluorescein-guided confocal laser endomicroscopy for the detection of ipilimumab-induced colitis.

Endoscopy·2012
Same author

Search for dilepton resonances in pp collisions at √s=7 TeV with the ATLAS detector.

Physical review letters·2012
Same journal

IL-33 scripts cancer immunity.

Trends in immunology·2026
Same journal

Mitochondrial Ca<sup>2+</sup> signaling: A metabolic rheostat defining tumor and immune cell fate.

Trends in immunology·2026
Same journal

Cross-priming underlies the efficacy of antibody-drug conjugates and immunotherapy combinations.

Trends in immunology·2026
Same journal

Gut microbiome metabolites meet immunometabolism in inflammatory bowel disease.

Trends in immunology·2026
Same journal

Metabolic regulatory nodes of the inflammasome and inflammatory cell death.

Trends in immunology·2026
Same journal

Parental leave in immunology - 6.

Trends in immunology·2026
See all related articles

Viral vectors engineered to express tumor antigens or cytokines offer a promising strategy for dendritic cell (DC) immunotherapy. Ex vivo transduction enhances control over DC quality and antigen delivery for improved cancer treatment.

Area of Science:

  • Immunology
  • Oncology
  • Gene Therapy

Background:

  • Dendritic cells (DCs) are crucial for initiating anti-tumor immune responses.
  • DC-based immunotherapy aims to enhance the immune system's ability to target cancer cells.
  • Viral vectors offer efficient gene delivery for modifying DCs.

Purpose of the Study:

  • To review viral vectors engineered for DC transduction in cancer immunotherapy.
  • To evaluate the potential of these vectors for expressing tumor-associated antigens (TAAs) and cytokines.
  • To discuss the advantages of ex vivo DC manipulation.

Main Methods:

  • Literature review of current viral vector technologies for DC transduction.
  • Analysis of viral vector systems designed for TAA or cytokine expression.

Related Experiment Videos

  • Evaluation of ex vivo transduction methods for DC immunotherapy.

    • Main Results:

    • Viral vectors can achieve high transgene expression levels in DCs.
    • Ex vivo transduction provides control over DC quality, antigen load, and re-injection site.
    • Various viral vector platforms are under development for DC-based immunotherapy.

    Conclusions:

    • Genetically engineered viral vectors are a powerful tool for DC-based cancer immunotherapy.
    • Ex vivo transduction of DCs with viral vectors holds significant therapeutic potential.
    • Further development of viral vector systems is key to advancing DC immunotherapy.